Dissecting Gram-negative envelope biogenesis
Lead Research Organisation:
University of Birmingham
Department Name: Sch of Biosciences
Abstract
The World Health Organization (WHO) identified antibiotic resistant pathogens as one of the biggest threats to global health, food security and development. Anyone can be affected, regardless of age or nationality. The growing number of pathogens that are resistant to current antibiotic treatments clearly signal a need to act against these rapidly adapting pathogens. Despite access to the most modern medicines and hospitals, non-treatable infections impact patients in several ways, ranging from longer hospital stays, to ultimately death. Thus, there is an urgent need to invest more resources in research on pathogens to be able to treat infections they cause. Therefore, the WHO issued a warning to act to prevent us from heading for a post-antibiotic area, where common infections and minor injuries would once again be deadly. The WHO have prioritised a list of the most concerning pathogens to encourage funders like the BBSRC and scientists to tackle the pathogens that are close to becoming untreatable. At the top of this list, classed as critical, are solely Gram-negative bacteria. This research proposal focusses on understanding how Gram-negative bacteria build one of their most important structures - their cell envelope. Furthering our knowledge about this process will help us to design strategies to overcome pathogen resistance to the antibiotics we use.
The bacterial cell envelope is a multi-layered structure that protects the cell from its unpredictable and often hostile environment, including exposure to antibiotics. In particular, Gram-negative bacterial cell envelopes hold special interest because of the combined property of being both a structural element and a permeability barrier. The low permeability is conferred by the asymmetric lipid bilayer, referred to as the outer membrane, which prevents toxic compounds, including many antibiotics, from entering the cell. Defining which genes play a role in maintaining the structure and impermeability of the envelope is fundamental to understanding how bacteria protect themselves. It also helps us to find new ways to overcome this permeability barrier and to deliver antibiotics to treat infections. Despite the need for this kind of research, genome-wide screens to assay envelope integrity in Gram-negative bacteria are still missing. The work outlined in this proposal will fill this knowledge gap. I will develop a genome-wide, high-throughput assay to robustly quantify the underlying network of genes involved in Gram-negative envelope biosynthesis.
The function of any gene can be studied by deleting it from the genome and analysing the consequences of its deletion (e.g. differences in responses to antibiotics). This can be done systematically using thousands of mutants of a pathogen, each mutant deficient in a single gene. I propose to use a collection of single deletion mutants to profile envelope biogenesis for the Gram-negative pathogens Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumoniae. This work will uncover the effect of each deleted gene on responses to many different antibiotics and environmental stresses. The resulting stress-response maps will provide knowledge about the uncharted mode of action of drugs and how those bacteria maintain their envelope integrity when challenged. By analysing these networks, I can identify genes that play fundamental roles in these processes.
Once I have identified important genes or pathways, I will further investigate their cellular function. For this, I will use my expertise in molecular biology to understand if other genes are co-dependent on identified key players (genetic interactions) and if we can identify the protein machineries these proteins are part of (protein interactions). These observations will aid in the identification of potential drug targets and help to overcome the molecular barrier posed by the cell envelope, ultimately leading to better treatment of Gram-negative bacterial infections.
The bacterial cell envelope is a multi-layered structure that protects the cell from its unpredictable and often hostile environment, including exposure to antibiotics. In particular, Gram-negative bacterial cell envelopes hold special interest because of the combined property of being both a structural element and a permeability barrier. The low permeability is conferred by the asymmetric lipid bilayer, referred to as the outer membrane, which prevents toxic compounds, including many antibiotics, from entering the cell. Defining which genes play a role in maintaining the structure and impermeability of the envelope is fundamental to understanding how bacteria protect themselves. It also helps us to find new ways to overcome this permeability barrier and to deliver antibiotics to treat infections. Despite the need for this kind of research, genome-wide screens to assay envelope integrity in Gram-negative bacteria are still missing. The work outlined in this proposal will fill this knowledge gap. I will develop a genome-wide, high-throughput assay to robustly quantify the underlying network of genes involved in Gram-negative envelope biosynthesis.
The function of any gene can be studied by deleting it from the genome and analysing the consequences of its deletion (e.g. differences in responses to antibiotics). This can be done systematically using thousands of mutants of a pathogen, each mutant deficient in a single gene. I propose to use a collection of single deletion mutants to profile envelope biogenesis for the Gram-negative pathogens Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumoniae. This work will uncover the effect of each deleted gene on responses to many different antibiotics and environmental stresses. The resulting stress-response maps will provide knowledge about the uncharted mode of action of drugs and how those bacteria maintain their envelope integrity when challenged. By analysing these networks, I can identify genes that play fundamental roles in these processes.
Once I have identified important genes or pathways, I will further investigate their cellular function. For this, I will use my expertise in molecular biology to understand if other genes are co-dependent on identified key players (genetic interactions) and if we can identify the protein machineries these proteins are part of (protein interactions). These observations will aid in the identification of potential drug targets and help to overcome the molecular barrier posed by the cell envelope, ultimately leading to better treatment of Gram-negative bacterial infections.
Publications
Boelter G
(2022)
The lipoprotein DolP affects cell separation in Escherichia coli, but not as an upstream regulator of NlpD.
in Microbiology (Reading, England)
Doherty H
(2023)
ChemGAPP: a tool for chemical genomics analysis and phenotypic profiling
in Bioinformatics
Franklin A
(2024)
Author Correction: The mycobacterial glycoside hydrolase LamH enables capsular arabinomannan release and stimulates growth.
in Nature communications
Franklin A
(2024)
The mycobacterial glycoside hydrolase LamH enables capsular arabinomannan release and stimulates growth
in Nature Communications
Franklin A
(2023)
The mycobacterial glycoside hydrolase LamH enables capsular arabinomannan release and stimulates growth.
in bioRxiv : the preprint server for biology
Goodall E
(2022)
LI-Detector: a Method for Curating Ordered Gene-Replacement Libraries
in Microbiology Spectrum
Graham CLB
(2024)
Membrane staining and phospholipid tracking in Pseudomonas aeruginosa PAO1 using the phosphatidylcholine mimic propargyl-choline.
in Access microbiology
Related Projects
| Project Reference | Relationship | Related To | Start | End | Award Value |
|---|---|---|---|---|---|
| MR/V027204/1 | 01/03/2022 | 29/06/2023 | £1,067,224 | ||
| MR/V027204/2 | Transfer | MR/V027204/1 | 30/06/2023 | 28/02/2026 | £717,382 |
| Description | With this award we try to understand how Gram-negative bacteria build their protective envelope. This knowledge is key to find new ways to treat Gram-negative pathogens with antibiotics. Our strategy here is to identify weak points that can make the envelop leaky, as this will increase the effectiveness of antibiotics currently available to us. Year1: We currently work on the model organism Escherichia coli as understanding how Gram-negative envelope biogenesis works here can help us to design better experiments using other Gram-negative pathogens. We explored the function of NlpI (Aim3) in relation to enzymes that are important to build the structural scaffold of the cell envelope (peptidoglycan). These findings will be published soon and explore is NlpI is a good drug target. In another story we found a completely novel link between envelope biogenesis and how E. coli replicate their DNA. That is very exciting as it could have important implications to understand how bacteria coordinate their growth processes. We currently finalise this manuscript and can hopefully make it available to the research community within a few weeks. Sadly we couldn't perform the proposed CPRG screen yet, as due to supply chain issues arising from Covid, we were unable to secure enough quantity of the compound in year one. Year2: We moved our laboratory to the Newcastle University. In all honesty this move set us back a few months, but due to the better research environment and support for the screening facility it still made sense. The FLF committee also approved the move due to those reasons. We were able now to buy enough CPRG, though I decided to delay the screen to summer 2024 when the Newcastle laboratory is fully set-up. However in the meantime we used a chemical genomics approach to better understand the interplay between penicillin binding proteins and peptidoglycan hydrolases. This is a major part of AIM 3 of the initial grant and we just published this in mBio. We also advance our TraDIS techniques and used it to dissect the non-essential sub-units of the BAM-complex. This manuscript is currently on bioxriv after it was send out to review to EMBO J, but sadly rejected. We are thinking of sending it to eLIFE shortly. |
| Exploitation Route | It is a bit too early to say, as we just started the work and couldn't publish our findings yet. However, our ChemGAPP software is already widely used and we got very good feedback on twitter on our latest manuscripts. In general our laboratory is extremely productive and highly cited. So I think that can be used as an indication that our work is relevant for our field. |
| Sectors | Agriculture Food and Drink Education Healthcare Manufacturing including Industrial Biotechology Other |
| Description | Cross talk between DNA replication and LPS biosynthesis during cell growth |
| Amount | £437,202 (GBP) |
| Funding ID | BB/Y001265/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 02/2027 |
| Title | ChemGAPP |
| Description | Abstract Motivation High-throughput chemical genomic screens produce informative datasets, providing valuable insights into unknown gene function on a genome-wide level. However, there is currently no comprehensive analytic package publicly available. We developed ChemGAPP to bridge this gap. ChemGAPP integrates various steps in a streamlined and user-friendly format, including rigorous quality control measures to curate screening data. Results ChemGAPP provides three sub-packages for different chemical-genomic screens: ChemGAPP Big for large-scale screens; ChemGAPP Small for small-scale screens; and ChemGAPP GI for genetic interaction screens. ChemGAPP Big, tested against the Escherichiacoli KEIO collection, revealed reliable fitness scores which displayed biologically relevant phenotypes. ChemGAPP Small demonstrated significant changes in phenotype in a small-scale screen. ChemGAPP GI was benchmarked against three sets of genes with known epistasis types and successfully reproduced each interaction type. Availability and implementation ChemGAPP is available at https://github.com/HannahMDoherty/ChemGAPP, as a standalone Python package as well as Streamlit applications. |
| Type Of Material | Data analysis technique |
| Year Produced | 2023 |
| Provided To Others? | Yes |
| Impact | This is currently the state of the art analysis tool package to analyse chemical genomics data |
| URL | https://github.com/HannahMDoherty/ChemGAPP, |
| Description | Envelope Biology and DNA replication |
| Organisation | University of Gdansk |
| Country | Poland |
| Sector | Academic/University |
| PI Contribution | We are working together to identify a possible metabolic link between DNA replication and Outer membrane biogenesis in Gram-negative bacteria. This resulted in a BBSRC grant with Monika being a non-funded collaborator. It also has resulted in a Polish PhD student grant where I am a non-funded collaborator. |
| Collaborator Contribution | Monika provides expertise around DNA replication, an area of research we were unfamiliar. However based on our results, it seems plausible that there is a connection between our research interest, the Gram-negative envelope and DNA replication. Hence we reached out to start this collaboration. |
| Impact | https://doi.org/10.1128/mbio.00325-24 https://doi.org/10.1101/2023.07.05.547807 https://doi.org/10.1099/mic.0.001197 |
| Start Year | 2022 |
| Description | Systems Biology for Gram-negative bacteria |
| Organisation | King Abdullah University of Science and Technology (KAUST) |
| Country | Saudi Arabia |
| Sector | Academic/University |
| PI Contribution | Together with Danesh we closely work to develop systems methods for bacterial pathogens. Currently our focus is on Gram-negative bacteria, but in the future we likely adapt our approaches to all bacterial pathogens. In the UK we mainly develop the wet lab side of our projects, whereas at KAUST a lot of our software and data analysis packages are created. |
| Collaborator Contribution | Danesh helps us to create software packages and trains my students remotely in bioinformatics |
| Impact | Together we created ChemGAPP a novel chemical genomics platform. Its listed as output in this submission. As we closely work with Danesh on all aspects of data-analysis he co-authored most my publications as we co-supervise all our dry-lab staff together. |
| Start Year | 2022 |
| Description | Bioscience open day |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | The University of Birmingham organises once a year an open science day for local schools and the general audience to attend with talks, posters and general discussions about the impact of biology/biotechnology on daily life. |
| Year(s) Of Engagement Activity | 2021,2022,2023,2024 |
| Description | King Edward VI Camp Hill School for Girls |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | I gave a seminar to A-level Biology students about systems microbiology and we had a debate about biotechnology may shape our future world. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Working with cap-a-pie (theatre group) on teaching infectious disease to school children using theatre |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | We have an ongoing collaboration with the theatre charity cap-a-pie that teaches children biology and other subjects using theatre and dance. We helped and consulted cap-a-pie volunteers about the correctness of the science, but also attended the workshops with school kids (aged 6 to 12) and helped running the workshops. https://www.cap-a-pie.co.uk/ |
| Year(s) Of Engagement Activity | 2024 |
| URL | https://www.cap-a-pie.co.uk/ |
